Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study

What Was Tested

The paper reports a study of Somatostatin and Triptorelin, published as a randomized controlled trial.

To evaluate prospectively the combination of a luteinizing hormone-releasing hormone analog with a somatostatin analog and dexamethasone in patients with hormone-refractory prostate cancer (HRPC) in a randomized Phase II study.

HRPC presents a challenging therapeutic problem.

Salvage chemotherapy is the usual approach at this stage of the disease.

Who Took Part

PubMed indexes the participants as middle-aged adults, older adults and people over 80, men only.

Forty patients with HRPC were randomized to receive one of two treatments.

How the Study Was Run

The researchers set it up as a randomized study.

Because people in this Somatostatin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The clinical and prostate-specific antigen (PSA) response, overall survival, time to progression, and toxicity were compared between the two groups.

What Was Measured

The subject headings attached to it are Adenocarcinoma, Antineoplastic Agents, Hormonal, Antineoplastic Combined Chemotherapy Protocols, Bone Neoplasms, Combined Modality Therapy, Dexamethasone and Diabetes Mellitus.

What This Means in Plain Language

The paper is a randomized study of Somatostatin and Triptorelin.

The abstract goes on to report its results in about 12 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2004 (Urology), a journal based in United States.

More context: the Somatostatin compound page and the Triptorelin compound page, all human trials.